The incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), play an important role in glucose homeostasis by potentiating glucose-induced insulin secretion. Furthermore, GLP-1 has been reported to play a role in glucose homeostasis by inhibiting glucagon secretion and delaying gastric emptying. As the insulinotropic effect of GLP-1 is preserved in patients with type 2 diabetes (T2D), therapies based on GLP-1 have been developed in recent years, and these have proven to be efficient in the treatment of T2D. The endogenous secretion of both GIP and GLP-1 is stimulated by glucose in the small intestine, and the release is dependent on the amount. In this work, we developed a semimechanistic model describing the release of GIP and GLP-1 after ingestion of various glucose doses in healthy volunteers and patients with T2D. In the model, the release of both hormones is stimulated by glucose in the proximal small intestine, and no differences in the secretion dynamics between healthy individuals and patients with T2D were identified after taking differences in glucose profiles into account.
It has long been known that an oral glucose tolerance test (OGTT) induces a greater insulin response than an isoglycaemic intravenous glucose infusion (IIGI) [1] . This phenomenon, which is termed the incretin effect, is caused by hormones secreted from the gastrointestinal (GI) tract after ingestion of nutrients, that is glucose and lipids. Although lipids have been reported to be the most potent of these two [2] , glucose is by far the most studied due to its importance in diabetes. Clinically, the most important incretin hormones are glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Both hormones potentiate glucose-stimulated insulin secretion. Furthermore, GLP-1 plays a role in glucose homeostasis by inhibiting glucagon secretion and delaying gastric emptying [3] . The release of GIP and GLP-1 after nutrient ingestion is dependent on both the composition and the amount of ingested nutrients [4] . GIP is released from the K cells, which are mainly located in the proximal part of the small intestine, the duodenum and the proximal jejunum [3] . GLP-1 is released from L cells, which are mainly located in the distal part of the small intestine (ileum) and in the colon. However, L cells are also found in the proximal small intestine [1] . After glucose ingestion, a rise in GLP-1 concentration is observed after 10-15 min. As the density of L cells primarily appears highest in the distal small intestine and colon, it has been proposed that this early rise in GLP-1 is caused by indirect neural and/or hormonal 'proximal-to-distal' mediators from the upper intestine to distally located L cells. However, as the L cells are found throughout the small intestine, it is also possible that the early rise in GLP-1 concentration is caused by direct contact of glucose with L cells in the proximal part of the small intestine [5, 6] . Both GLP-1 and GIP are rapidly inactivated in plasma by the enzyme dipeptidyl peptidase 4 (DDP-4) resulting in a short plasma half-life for the peptides in the circulation.
Patients with type 2 diabetes (T2D) are characterized by an impaired incretin effect [7] . However in high doses, GLP-1 is a potent glucose-lowering agent in patients with T2D, and GLP-1 receptor agonism has been developed pharmacologically into effective antidiabetic therapies. They can be divided into two groups: (i) DPP-4 inhibitors, such as vildagliptin and sitagliptin, which decrease inactivation of GLP-1 (and GIP), and (ii) GLP-1 receptor agonists, such as liraglutide and exenatide.
Understanding how GIP and GLP-1 responses after glucose ingestion depend on the size of the glucose load is an important link in understanding their effect on glucose homeostasis. The objective of this work was to develop a semimechanistic model describing the incretin hormone release after ingestion of different glucose loads and investigate differences between healthy individuals and patients with T2D in the secretion dynamics.
Methods
Data. For model development, data from a previously published study [7] were used. In this study, eight patients with T2D and eight Author for correspondence: Maria C. Kjellsson, Department of Pharmaceutical Biosciences Box 591 751 24 Uppsala, Sweden (e-mail maria.kjellsson@farmbio.uu.se).
gender-, age-and body mass index (BMI)-matched healthy individuals were studied on six occasions in a full cross-over study with the arms: 25-, 75-and 125-g OGTTs and three corresponding IIGIs. A summary of the demographics is given in table 1. On the OGTT days, the participants ingested the glucose dose dissolved in 300 ml water containing 1.5 g acetaminophen. Blood samples were drawn 15, 10 and 0 min. before and 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 90 , 120, 150, 180 and 240 min. after ingestion of glucose, for the assay of plasma glucose, C-peptide, insulin, GIP, GLP-1 and acetaminophen. In the model development, GIP and GLP-1 data from the OGTTs as well as acetaminophen and plasma glucose were used.
GIP and GLP-1 model. Both GIP and GLP-1 concentrations were described by indirect response models [8] where the zero-order rate constant for production k in is stimulated by glucose G in the small intestine; that is, the concentrations C of both hormones were governed by
where k out defines the first-order rate constant for removal of C. At steady state, the concentration is given by C SS = F(G) Á k in /k out with F(G) = 1. For both hormones, it was assumed that the rate of production was stimulated by glucose in the small intestine, represented in the model by the function F(G). As the K cells and L cells, secreting GIP and GLP-1, respectively, are distributed differently throughout the small intestine, model-predicted glucose in the different parts of the intestine was used to drive the function F(G). A previously published model for gastric emptying and glucose absorption (GEGA) [9] was used to predict the dynamics of glucose in duodenum, jejunum and ileum. This model is described shortly below. Linear, power, E max and sigmoidal E max models were tested for F(G) with the three different predictors of G: G D (glucose amount in duodenum), G J (glucose amount in jejunum) and G I (glucose amount in ileum).
Glucose absorption and gastric emptying models. In the mechanistic GEGA model, the intestinal glucose amount was described by a transit model, consisting of four compartments representing stomach, duodenum, jejunum and ileum. The small intestinal transit time (SITT) was set to 4 hr, and transit times of duodenum, jejunum and ileum were fixed to 8, 37 and 55% of SITT, respectively [10] . The absorption of glucose was assumed to be negligible in the stomach and to be saturable over the three intestinal segments, with different maximal glucose absorption rates in the three segments but with the same affinity. The rate of gastric emptying was derived using acetaminophen as biomarker. As acetaminophen is poorly absorbed in the stomach and rapidly absorbed in the duodenum, it is commonly used as a marker for gastric emptying [11] . Disposition and elimination of acetaminophen were described by a two-compartment model and gastric emptying by two transit compartments: stomach and small intestine, with the acetaminophen absorption rate fixed to be fast (half-life of 5 min.). A lag time and a saturable first-pass effect were also included in the model [9] . As current knowledge states that the gastric emptying is inhibited by both glucose and GLP-1, the GLP-1 effect on the gastric emptying rate k SD was investigated, assuming GLP-1 concentration in plasma inhibits the rate.
Parameter estimation and model selection. The analysis was performed with nonlinear mixed-effects modelling in NONMEM 7 [12] with the first-order conditional estimation (FOCE) method and the differential equation solver ADVAN13. The model development was guided by mechanistic considerations, objective function value (OFV), plausibility of parameter estimates and graphical assessment. A difference in the OFV of at least 10.83 was used as cut-point value for nested models differing by one parameter, which corresponds to a significance level of a = 0.001 according to the likelihood ratio test (LRT). The internal evaluation and predictive properties of the model were assessed by visual predictive check (VPC).
Interindividual variability. The differences between individual parameters were described using random effects, which were assumed to be normally distributed with mean zero, and a variance, which was estimated. The distribution of the individual parameters around the typical population value was assumed to be log-normal.
Residual error model. The differences between the logarithm of the observed plasma concentrations and the logarithm of the predicted plasma concentrations were described using an additive residual error term, which was assumed to arise from a normal distribution with mean zero and a variance, which was estimated.
Covariate model. As the concentration versus time profiles of GLP-1 and GIP were similar between the healthy individuals and the T2D patients [7] , the models were first developed assuming no difference between the populations. Difference between healthy individuals and the T2D patients were then investigated allowing one parameter at a time to differ between the two populations, assessing the change in OFV as well as changes in VPCs.
Results

Gastric emptying model with GLP-1 inhibition.
Inclusion of GLP-1 concentration inhibition on the gastric emptying rate constant resulted in a statistical improvement over the model without this inhibition, as judged by OFV. However, the uncertainty of the parameter estimate related to GLP-1 inhibition was high (RSE = 430%), and no impact of this effect could be seen in the VPCs. Thus, GLP-1 inhibition was not included in the GEGA model. GIP model. An indirect response model described GIP concentrations well, and as the half-life of GIP is known to be approximately 5-7 min. [13] , the elimination rate constant was fixed to k out,GIP = ln(2)/6 min À1 = 0.12 min
À1
. Estimating k out,GIP gave identical results, however, with large uncertainty of the estimate, and thus, the value was fixed based on knowledge of physiology. The concentration of GIP was governed by 
where GIP SS is the GIP concentration at baseline, that is steady state, and
where a GIP is the slope of the relationship between G D (t) and k in,GIP , G D (t = 0) = 0 and thus, F GIP (G D (t = 0)) = 1. According to the LRT, there was no statistically significant difference between models with sigmoidicity and models without sigmoidicity (linear versus power: DOFV = À7.7; E max versus sigmoidal E max : DOFV = À7.2; df = 1). The uncertainty of the effect parameters was also lower with the lower complexity of the model. An E max function would be more physiologically plausible; however, there was no statistically significant difference between the linear and the E max model (DOFV = À0.15, df = 1). Thus, the more parsimonious model was chosen with better parameter precision. The effect of either G D (t), G J (t) or G I (t) was tested individually. The model with duodenal glucose concentrations driving the stimulation gave the lowest OFV (41 and 164 points lower than the model with jejunal and ileal glucose amount, respectively). As K cells are primarily found in the proximal small intestine, it seems reasonable that the model including the stimulatory effect of glucose in the duodenum gives the best model fit. Inclusion of additional stimulatory effect of either jejunal or ileal glucose amount gave no further improvement of the model fit.
GLP-1 model.
Also, the GLP-1 concentrations were well described by the indirect response model. Total GLP-1 has a half-life of 4 min. [14] , and thus, the elimination rate constant was fixed to k out,GLP1 = ln (2)/4 min À1 = 0.17 min À1 Also for GLP-1, estimating k out,GLP1
gave the same fit to the data as fixing to physiological values, but with large parameter uncertainty, and thus, the parameter was fixed. The concentration of GLP-1 was governed by
in which
where GLP1 SS is the GLP-1 concentration at baseline, that is steady state, and
where a GLP1 is the slope of the relationship between G J (t) and
According to the LRT, the sigmoidal E max model was superior to the E max model; however, the power model was not superior to the linear model (linear versus power: DOFV = À2.3; E max versus sigmoidal E max : DOFV = À21.1; df = 1). The sigmoidal E max model was also superior in fit compared to the linear model (DOFV = À23.4, df = 2). The uncertainty of the parameters of the more complex model was, however, high, and thus, the less complex, linear model was preferred.
The effect of either G D (t), G J (t) or G I (t) was also tested individually for GLP-1. The model with jejunal glucose concentrations driving the stimulation gave the lowest OFV (13 and 26 lower than the model with duodenal and ileal glucose amount, respectively). Inclusion of additional stimulatory effect of either duodenal or ileal glucose amount did not improve the model fit.
Model performance and validation of the final model. A schematic illustration of the final model is shown in fig. 1 , and parameter estimates are given in table 2. Overall, the model described the main trend in the data well as observed from fig. 2 where prediction-corrected VPCs for the GIP and GLP-1 are shown, respectively. The variability in the model is Fig. 1 . Schematic illustration of the combined model for acetaminophen, glucose, GIP and GLP-1. The gastric emptying and glucose absorption model are described in detail in a paper by Alsk€ ar et al. [9] . Glucose model: G S : glucose in the stomach. G D : glucose in the duodenum. G J : glucose in the jejunum. G I : glucose in the ileum. k SD : gastric emptying rate. k DJ : transfer rate of glucose from duodenum to jejunum. k JI : transfer rate of glucose from jejunum to ileum. RA maxX : glucose absorption rate from X, with X being duodenum, jejunum and ileum. K mG : glucose amount in small intestine giving 50% of maximal first-pass effect. FP G : first-pass effect for glucose. GLP-1 model: k in,GLP1 : rate of production of GLP-1. k out,GLP1 : elimination rate for GLP-1. GLP-1: concentration of GLP-1. GLP-1 model: k in,GIP : rate of production of GIP. k out,GIP : elimination rate for GIP. GIP: concentration of GIP. Acetaminophen model: AC S : amount of acetaminophen in stomach. AC I : amount of acetaminophen in intestine. k a : absorption rate from intestine to plasma. V maxAC : maximum rate of first-pass metabolism. K mAC : acetaminophen amount in small intestine giving 50% of maximal first-pass effect. G PLASMA and AC PLASMA represent models of disposition and elimination of glucose and acetaminophen, respectively. fairly well captured; however, the confidence interval around the 5th and 95th prediction intervals is wide. The confidence of the outer prediction intervals is limited due to the low number of individuals in the study, although all OGTTs and both healthy and diabetic individuals are shown in fig. 2 . Diagnostic plots for the evaluation of the quality of the model fit (i.e. observations versus population predictions, observations versus individual predictions, weighted residuals versus time) showed that the model described the data adequately (see Figures S1-S5 in Appendix S2). The model also described the main trend of each glucose dose (25-, 75-and 125-g) well (see Figure S6 in Appendix S2).
Correlation between all parameters was investigated. Estimating the model with a full covariance matrix, compared to a diagonal covariance matrix, gave a decrease in OFV of 23.5 points. However, some of the correlations were estimated with large uncertainty and a model where all correlations were removed except between baseline GLP-1 and a GLP1 as well as between baseline GIP and a GIP performed equally well as the full model (DOFV = 2.19).
The correlation between residuals of GIP and GLP-1, included as the concentrations were determined in the same sample, was estimated to only 14.5%, although with a sufficient certainty (RSE 14.1%). Removing the correlation increased the uncertainty of the parameters, and the correlation was retained in the final model.
Covariate relationship.
For the final models of GIP and GLP-1, a difference in parameter estimates between healthy individuals and patients with T2D was investigated. Allowing a difference between these populations did not result in any improvement in fit. The largest drop in OFV was observed for allowing different a GIP values for healthy individuals and patients with T2D (DOFV = À2.1, df = 1). There was no visible difference in the VPCs for healthy individuals and patients with T2D, as shown by fig. 3 , in which the models, without disease state differences in parameters, are shown to equally well describe the data for healthy individuals and patients with T2D. Only disease state was investigated as covariate. Another potentially useful covariate would be disease duration. However, as all patients were newly diagnosed (table 1), disease duration was not investigated as a covariate due to the homogeneity of the covariate.
Discussion
Incretin hormones play a major role in glucose homeostasis. In recent years, several incretin-based therapies have been developed, and these have proven efficient in the treatment of patients with T2D [15] . Understanding the secretion pattern of incretin hormones will provide an important link in understanding their effects on glucose homeostasis. The aim of the current work was to develop a semimechanistic model describing the incretin response after ingestion of varying glucose loads and investigate difference in the secretion between healthy individuals and T2D patients, while accounting for differences in glucose exposure. Previous models of incretin hormones have mostly focused on describing the response after a 75-g OGTT [16, 17] , and the effect of the glucose load on the secretion pattern has to our knowledge not been investigated before.
In the model development, data from a previous study [7] were used. In this study, patients with T2D and healthy individuals underwent three OGTTs with different glucose loads. Secretion of incretin hormones is stimulated by glucose in the small intestine; however, no observations of glucose in the small intestine were available in this study. Instead, the previously published GEGA model [9] was used to predict the expected glucose available in the three main parts of the small intestine: duodenum, jejunum and ileum. It has previously been shown that GLP-1 at physiological levels inhibits gastric emptying [18, 19] and as the GEGA model did not include GLP-1 inhibition of gastric emptying, this inhibition was reinvestigated in this work. Although the effect of GLP-1 concentrations on gastric emptying was found to be statistically significant, the parameter associated with the inhibition could not be determined with sufficient certainty. This is most likely a consequence of the strong effect of glucose, shifting the gastric emptying close to maximum inhibition, disguising the additional inhibition of GLP-1. To characterize and quantify the GLP-1 inhibition on gastric emptying, a different study design, with a shifted, relative importance between GLP-1 and glucose, would be needed. The inability of the model to identify this relationship with the current data should not be interpreted as a physiological lack of effect. 3 Derived from k in = k out * GIP SS /GLP1 SS.
The release of both GLP-1 and GIP was assumed to be direct in relation to stimulation of K and L cells by glucose in the small intestine. This stimulation is most likely driven by the glucose concentration in the proximity of these cells. The GEGA model predicts the glucose amount (not the concentration) in the various parts of the small intestine, and thus, the parameters describing the stimulation of incretin secretion are in units of amount, that is grams of glucose. As discussed by the authors of the GEGA model [9] , predicting the glucose concentration gradient in the small intestine requires additional functions of the intestinal water gradient, which was not included in the GEGA model. However, if the glucose dilution is assumed to be constant and only that of starting dilution (300 ml), the parameters of stimulation would correspond to a GIP = 0.081 mM À1 and a GLP1 = 0.064 mM À1 for GIP and GLP-1 stimulation, respectively, with a clear glucose dose relationship for the 25-and 75-g glucose doses (see Figure S6 in Appendix S2). The relationship is less clear perhaps for the highest glucose dose as the maximum glucose in the intestine is not increased with a higher dose. However, glucose exposure is prolonged, which is related to glucose inhibition of gastric emptying. A few studies have been performed investigating the relationship between intestinal glucose concentration and GLP-1 secretion. These studies show that with perfused animal ileum, the glucose concentrations that trigger GLP-1 release range from 5 mM to 1 M [20] [21] [22] [23] [24] . These glucose concentrations correspond to model-predicted GLP-1 of 22 and 1090 pM, respectively; 5 and 1073 pM above baseline 
GIP T2D − all glucose doses Fig. 3 . Prediction-corrected visual predictive check comparing observed and simulated GIP (top) and GLP-1 (bottom) data during the oral glucose tolerance tests for healthy individuals (left panels) and T2D patients (right panels). The solid and dashed lines are the 5th, 50th and 95th percentiles of the observed data. Black dots are observations. Shaded area is the 95% confidence interval around the 5th, 50th and 95th percentiles of the simulated data.
secretion. The range of jejunal glucose in this work ranged from 0 to 80 mM, and thus, the GLP-1 prediction of jejunal glucose concentration of 1 M is highly uncertain. Xu et al. [23] and Hansen et al. [24] also performed concentration-response experiments showing that the higher the glucose exposure, the higher the GLP-1 secretion. Figure 4 shows the model-predicted relationship between glucose concentrations and GLP-1 and GIP concentrations. However, fig. 4 and the studies performed by Xu et al. [23] and Hansen et al. [24] assume constant glucose concentration until steady-state secretion has been reached and not dynamic as in the case of an OGTT. In this study, we show that using a mathematical model, the dynamic glucose-response relationship could be characterized and quantified, although the predicted secretion in the higher glucose range is highly uncertain. In both models of GIP and GLP-1 secretion, linear relationships were identified, a relationship lacking a limit of maximum capacity. Most physiological processes have a natural maximum capacity, and although not identified in the current study, theoretically GIP and GLP-1 have such limits. As seen from the model predictions in fig. 4 , the relationship between GIP and GLP-1 secretion and duodenal and jejunal concentrations is highly uncertain above 150 and 30 mM, respectively, and it seems the study design was not appropriate for characterizing the upper limits of GLP-1 and GIP secretion. Using the same study design with a higher glucose dose is, however, unlikely to increase the power to characterize the maximum GLP-1 and GIP secretion, due to the inhibitory effect of duodenal glucose concentrations on the gastric emptying, dampening the intestinal glucose concentrations. Thus, it seems as if the maximum GLP-1 and GIP secretion capacity cannot be characterized with an OGTT. As mentioned in the introduction, lipids, in addition to glucose, have a stimulatory effect on GIP and GLP-1 secretion and it is plausible that a meal tolerance test, including lipids, would result in a different secretion behaviour and thus maybe with the possibility of characterizing the maximum secretion of GLP-1 and GIP.
Glucose-dependent insulinotropic polypeptide, as compared to GLP-1, has been reported to have a much stronger dose relationship with glucose and GIP concentrations increasing several hundred pM is not uncommon to see, while GLP-1 secretion is much more limited [25] . The models of GLP-1 and GIP predict the same behaviour with a much higher stimulation of GIP as compared to GLP-1, much contributed by the higher glucose amount in duodenum compared to in jejunum. Comparing the slope estimates of GIP and GLP-1 reveals a marginally higher slope for GIP (1.50 versus 1.19/g), and the estimates were not statically significantly different from each other.
The secretion of GLP-1 and GIP was found to be stimulated by glucose in different parts of the intestine. This well represents the current knowledge of K and L cells distribution in relation to GLP-1 and GIP secretion. Compared with other models of GLP-1 release [16, 17] , we believe that the current model, using a physiological representation of glucose absorption along with the wider range of glucose doses better represents the current knowledge of physiology and thus enabled a more physiological description of the release of GLP-1 and GIP.
Bagger et al. [7] compared secretion behaviour in healthy individuals and patients with T2D performed using t-tests of peak and area-under-the curve (AUC) of GLP-1 and GIP. They found differences between healthy individuals and patients with T2D in baseline GIP secretion, and GLP-1 AUC of the lowest glucose dose, however, concluded that there were no major differences between the two groups. The mechanistic modelling approach described in this work accounts for differences between healthy individuals and patients with T2D with regard to their glucose absorption and thus differences in glucose amounts in the gastrointestinal tract. The GEGA model accounts for difference in bioavailability of glucose for patients and healthy individuals which also affects the gastric emptying as glucose is present in higher amounts for longer time in the gastrointestinal tract of healthy individuals. Despite this, we were unable to identify any differences in secretion of GLP-1 and GIP between healthy individuals and patients with T2D, thus supporting the conclusions by Bagger et al. Any differences seen in the response to incretin hormones between healthy individuals and patients with T2D are thus explained not by differences in secretion behaviour, but rather by a desensitization of the receptor for patients with T2D in the insulin response, and potentially also in the glucagon response.
In conclusion, we have successfully developed semimechanistic models describing the secretion of GIP and GLP-1 after ingestion of a large range of glucose doses and through modelling verified that the secretion of the hormones is similar for healthy individuals and patients with T2D. By linking the model with an insulin secretion model, the model can help elucidate the important role of incretin hormones in glucose metabolism and quantify the difference in incretin effect between healthy individuals and T2D patients.
